RxDoctor Payments Data

Margaret Liu, MD

Ophthalmology · San Francisco, CANPI 1033384748

Payments from drug & device makers

$23,980in general payments, 2019–2025

Across 187 payments — averaging $128.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$20K
  • Alcon$886
  • AbbVie$551
  • Kala Pharmaceuticals, Inc.$427
  • Bausch & Lomb Americas Inc.$218
  • Novartis$200
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$261%
  • Food & beverage$3,93599%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$23,980 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$289,789
Medicare patients
439
Services billed
1,657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast61$57,241
RocklatanNetarsudil Mesylat/Latanoprost65$34,010
RestasisCyclosporine25$22,900
Prednisolone Acetate402$21,864
LumiganBimatoprost33$19,703
Cyclosporine21$14,337
RhopressaNetarsudil Mesylate24$11,282
Ofloxacin308$4,865
SimbrinzaBrinzolamide/Brimonidine Tart24$4,770
Brimonidine Tartrate48$4,688
ProlensaBromfenac Sodium13$4,449
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$4,424
Alphagan PBrimonidine Tartrate11$2,993
Bromfenac Sodium17$2,699
Timolol MaleateTimolol Maleate/Pf12$1,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$218$57,24161 claims
AbbVieRestasis, Lumigan, Alphagan P$551$45,59769 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$130$45,29389 claims
AlconSimbrinza$886$4,77024 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$191$4,44913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →